MAFF review meeting agrees to Cartagena protocol safety status of transgenic silkworm variant

Following an application by the National Institute of Agricultural Sciences (NIAS), a risk assessment study group under MAFF cleared the use of HC-EGFP Bombyx mori recombinant silkworms. There may be future interest to explore the use of recombinant silkworms for the production of veterinary drugs.

Nikkei Biotech news releases, January 31 and February 3

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny